Advertisement

Hämostaseologische Probleme während der Knochenmarktransplantation: Pathogenese, Diagnose und Therapie

  • C. Salat
  • H. Riess

Zusammenfassung

Hämostaseprobleme sind bei Patienten, die sich einer Knochenmarktransplantation (KMT) unterziehen, häufig. Zumeist handelt es sich um weniger schwerwiegende Haut- und Schleimhautblutungen. Insbesondere nach einer Konditionierung mit Busulfan oder Cyclophosphamid werden hämorrhagische Zystitiden beobachtet. Gravierende Hämostasestörungen, wie gastrointestinale Blutungen, die zumeist im Rahmen der Spendergegen-Wirt-Reaktion („graft versus host disease“, GVHD) des Darmes auftreten, Blutungen des Zentralnervensystems oder hämorrhagische Myokarditiden sind seltener, können aber lebensbedrohlich oder tödlich verlaufen.

Eine weitere Komplikation mit hoher Letalitätsrate, die mit dem Hämostasesystem in Beziehung steht, stellt die Lebervenenverschlußkrankheit („veno-occlusive disease“, VOD) dar.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Atkinson K, Norrie S, Chan P et al. (1986) Hematopoietic progenitor cell function after HLA-identical sibling bone marrow transplantation: Influence of chronic graft-host disease. Int J Cell Cloning 4:203PubMedCrossRefGoogle Scholar
  2. Attal M, Huguet F, Rubie H et al. (1992) Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low dose heparin: a prospective randomised trial. Blood 79:2834–2840PubMedGoogle Scholar
  3. Baglin TP, Harper P, Marcus RE (1990) Venoocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplantation 5:439–441PubMedGoogle Scholar
  4. Bearman SI (1995) The syndrome of hepatic venoocclusive disease after bone marrow transplantation. Blood 85(11):3005–3019PubMedGoogle Scholar
  5. Bearman SI, Shuhart MC, Hinds MS, McDonald GB (1992) Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 80:2458–2462PubMedGoogle Scholar
  6. Bearman SI, Lee JL, Baron AE, McDonald GB (1997) Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 89:1501–1506PubMedGoogle Scholar
  7. Catani L, Gugliotta L, Mattioli Belmonte M et al. (1993) Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplantation 12:253–259PubMedGoogle Scholar
  8. Collins P, Roderick A, O’ Brien D et al. (1994) Factor Vila and other hemostatic variables following bone marrow transplantation. Thromb Haemost 72:28–32PubMedGoogle Scholar
  9. Devergie A, Scrobohaci ML, Drouet L et al. (1986) Changes in endothelial and coagulation parameters after allogeneic bone marrow transplant (BMT) as a mean of prediction of venoocclusive disease (VOD). Exp Haematol (Abstract) 14:430Google Scholar
  10. Eissner G, Kohlhuber F, Grell M et al. (1995) Critical involvement of transmembrane tumor necrosis factor α in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 86:4184–4193PubMedGoogle Scholar
  11. Faioni EM, Krachmalnikoff A, Bearman SI et al. (1993) Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of veno-occlusive disease of the liver. Blood 81:3458–3462PubMedGoogle Scholar
  12. First LR, Smith BR, Lipton J et al. (1985) Isolated thrombocytopenia after allogenic bone marrow transplantation: Existence of transient and chronic thrombocytopenic syndromes. Blood 665:368–374Google Scholar
  13. Gordon GB, Haire WD, Kessinger A et al. (1991) High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplantation 8:497–503PubMedGoogle Scholar
  14. Harper PL, Jarvis J, Jennings I et al. (1990) Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplantation 5:39–42PubMedGoogle Scholar
  15. Holler E, Kolb HJ, Möller A et al. (1990) Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 75:1011–1016PubMedGoogle Scholar
  16. Juckett M, Perry EH, Daniels BS, Weisdorf DJ (1991) Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplantation 7:405–409PubMedGoogle Scholar
  17. Kaufmann PA, Jones RB, Greenberg CS, Peters WP (1990) Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Cancer 66:515–521CrossRefGoogle Scholar
  18. Leblond V, Salehian BD, Borel C et al. (1993) Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. Bone Marrow Transplantation 11:299–305PubMedGoogle Scholar
  19. Minchinton RM, Waters AH (1985) Autoimmune thrombocytopenia and neutropenia after marrow transplantation (letter). Blood 66:752PubMedGoogle Scholar
  20. Panella TJ, Peters W, White JG et al. (1990) Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 65:1711–1716PubMedCrossRefGoogle Scholar
  21. Panzer S, Kiefel V, Bartram CR et al. (1989) Immune thrombocytopenia more than a year after allogeneic bone marrow transplantation due to antibodies against donor platelets with anti-PAI1 specificity: evidence for a host-derived immune reaction. Brit J Hematol 71:259–264CrossRefGoogle Scholar
  22. Salat C, Holler E, Reinhardt B et al. (1994) Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplantation 14:747–750PubMedGoogle Scholar
  23. Salat C, Holler E, Kolb HJ et al. (1997a) Endothelial cell markers in bone marrow transplant recipients with and without acute graft versus host disease. Bone Marrow Transplant 19:909–917PubMedCrossRefGoogle Scholar
  24. Salat C, Holler E, Kolb HJ et al. (1997 b) PAI-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 89:2184–2188PubMedGoogle Scholar
  25. Scrobohaci L, Drouet L, Monem-Mansi A et al. (1991) Liver veno-occlusive disease after bone marrow transplantation. Changes in coagulation parameters and endothelial cell markers. Thromb Res 63:509–519PubMedCrossRefGoogle Scholar
  26. Shulman HM, Gown AM, Nugent DJ (1987) Hepatic venoocclusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127:549–558PubMedGoogle Scholar
  27. Shulman HM, Fisher LB, Schoch HG et al. (1994) Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 19:1171–1178PubMedCrossRefGoogle Scholar
  28. Smith RE, Berg DD (1988) Coagulation defects in cyclosporin A treated allogeneic bone marrow transplant patients. Am J Hematol 28:137–140PubMedCrossRefGoogle Scholar
  29. Tschuchnigg M, Bradstock KF, Koutts J et al. (1990) A case of thrombotic thrombocytopenic purpura following bone marrow transplantation. Bone Marrow Transplantation 5:61–63PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • C. Salat
  • H. Riess

There are no affiliations available

Personalised recommendations